Search Within

Pamela R Drullinsky

Formats
  1. Meeting Abstract (58)
  2. Journal Article (31)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Breast Medicine Service (91)
  2. Department of Medicine (91)
  3. Solid Tumor Oncology Division (91)
  4. Survivorship Research (69)
  5. Epidemiology and Biostatistics (47)
  6. Population Sciences Research Program (46)

More Groups

People
  1. Andrew Zelenetz (35)
  2. Matthew Matasar (32)
  3. Anita Kumar (31)
  4. David Straus (31)
  5. Paul Hamlin (31)
  6. Alison Moskowitz (26)

More People

Years
  1. 2024 (4)
  2. 2023 (1)
  3. 2022 (9)
  4. 2021 (10)
  5. 2020 (8)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Blood (17)
  3. Breast Cancer Research and Treatment (10)
  4. Cancer Research (9)
  5. Hematological Oncology (6)
  6. Clinical Cancer Research (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Society of Hematology (17)
  3. American Association for Cancer Research (13)
  4. Springer (10)
  5. Elsevier Inc. (8)
  6. Wiley Blackwell (6)

More Publishers

Results (91)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer
    Review

    Drullinsky, P. R.; Hurvitz, S. A.
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Borrego, M. R.; Chia, S. K. L.; Juric, D.; Turner, N. C.; Drullinsky, P.; Lerebours, F.; Bianchi, G. V.; Nienstedt, C. C.; Ridolfi, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
    Journal Article

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C. L.; Caron, P. C.; Drullinsky, P.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save